Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Feb 13, 2025
Finance
Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report
Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more
BioCentury | Jan 28, 2025
Deals
Abbvie seeks molecular glue degraders from Neomorph
Also in BioCentury’s Deals Report, Novo licenses BACH1 inhibitor from Immvention, Arrivent-Lepu in ADC deal, and Sage rejects Biogen’s bid
BioCentury | Dec 6, 2024
Product Development
KCC2 activation nears inflection point
Ovid, Axonis and others are poised to take therapies against the long undruggable KCC2 to the clinic for neurological disorders
BioCentury | Dec 3, 2024
Deals
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more
Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Oct 9, 2024
Product Development
TYK2 best-in-class battleground expands with InnoCare data
In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device
BioCentury | Oct 1, 2024
Deals
Prime narrows gene editing focus with BMS deal
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
Items per page:
1 - 10 of 545